In this regard, a study showed that recombinant anti-EGFR CAR-T cells exhibit specific cytolytic activity against EGFR-positive tumor cells and can release cytokines, displaying potential in fighting NSCLC (85). The gene discussed is EGFR; the disease is neoplasm.